Skip to main content
Publications
Lytras T, Beckmeyer-Borowko A, Kogevinas M, Kromhout H, Carsin AE, Anto JM, Bentouhami H, Weyler J, Heinrich J, Nowak D, Urrutia I, Martinez-Moratalla J, Gullon JA, Pereira Vega A, Raherison Semjen C, Pin I, Demoly P, Leynaert B, Villani S, Gislason T, Svanes O, Holm M, Forsberg B, Norback D, Mehta AJ, Keidel D, Vernez D, Benke G, Jogi D, Toren K, Sigsgaard T, Schlunssen V, Olivieri M, Blanc PD, Watkins J, Bono R, Squillacioti G, Buist AS, Vermeulen R, Jarvis D, Probst-Hensch N, Zock JP. Cumulative occupational exposures and lung-function decline in two large general-population cohorts. Ann Am Thorac Soc. 2021 Feb;18(2):238-46. doi: 10.1513/AnnalsATS.202002-113OC
Ko DT, Khan AM, Kotrri G, Austin PC, Wijeysundera HC, Koh M, Chu A, Jackevicius CA, Lawler PR, Tu JV. Eligibility, clinical outcomes, and budget impact of PCSK9 inhibitor adoption: the CANHEART PCSK9 study. J Am Heart Assoc. 2018 Nov 6;7(21):e010007. doi: 10.1161/JAHA.118.010007
Anthony L, Horsch D, Ervin C, Kulke MH, Pavel M, Bergsland E, Caplin M, Oberg K, Warner R, Kunz P, Metz DC, Pasieka J, Pavlakis N, DiBenedetti D, Haydysch E, Yang QM, Jackson S, Arnold K, Law L, Lapuerta P. Assessing treatment benefit of telotristat etiprate in patients with carcinoid syndrome: patient exit interviews. Poster presented at the 2016 UKI NETS 14th National Conference; December 2016. London, UK. [abstract] Pancreas. 2016 Dec; 45(3):470. Previously presented at the 8th Symposium of the North American Neuroendocrine Tumor Society. doi: 10.1530/endoabs.46.P11